Spedra

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
24-11-2021
Ciri produk Ciri produk (SPC)
24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
10-03-2015

Bahan aktif:

avanafil

Boleh didapati daripada:

Menarini International Operations Luxembourg S.A.

Kod ATC:

G04BE10

INN (Nama Antarabangsa):

avanafil

Kumpulan terapeutik:

Drugs used in erectile dysfunction

Kawasan terapeutik:

Erectile Dysfunction

Tanda-tanda terapeutik:

Treatment of erectile dysfunction in adult men.In order for Spedra to be effective, sexual stimulation is required.

Ringkasan produk:

Revision: 13

Status kebenaran:

Authorised

Tarikh kebenaran:

2013-06-21

Risalah maklumat

                                54
B. PACKAGE LEAFLET
55
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SPEDRA 50 MG TABLETS
avanafil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Spedra is and what it is used for
2.
What you need to know before you take Spedra
3.
How to take Spedra
4.
Possible side effects
5.
How to store Spedra
6.
Contents of the pack and other information
1.
WHAT SPEDRA IS AND WHAT IT IS USED FOR
Spedra contains the active substance avanafil. It belongs to a group
of medicines called
phosphodiesterase type 5 (PDE5) inhibitors. Spedra is a treatment for
adult men suffering from
erectile dysfunction (also known as impotence). This is when you
cannot get, or keep a hard, erect
penis suitable for sexual activity.
Spedra works by helping the blood vessels in your penis to relax. This
increases the blood flow into
your penis, helping it stay hard and erect when you get sexually
excited. Spedra does not cure your
condition.
It is important to note that Spedra only works if you are sexually
stimulated. You and your partner will
still need to use foreplay to get ready for sex – just as you would
if you were not taking a medicine to
help you.
Spedra will not help you if you do not have erectile dysfunction.
Spedra is not for women.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE SPEDRA
DO NOT TAKE SPEDRA:
•
If you are allergic to avanafil or any of the other ingredients of
this medicine (listed in section 6)
•
If you are taking “nitrate” medicines for chest pain (angina),
such as amyl nitrite or glyceryl
trinitrat
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Spedra 50 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 50 mg of avanafil.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
Pale yellow oval tablets, debossed with “50” on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of erectile dysfunction in adult men.
In order for Spedra to be effective, sexual stimulation is required.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Use in adult men _
The recommended dose is 100 mg taken as needed approximately 15 to 30
minutes before sexual
activity (see section 5.1). Based on individual efficacy and
tolerability, the dose may be increased to a
maximum dose of 200 mg or decreased to 50 mg. The maximum recommended
dosing frequency is
once per day. Sexual stimulation is required for a response to
treatment.
_Special populations _
_Elderly(≥ 65 years old) _
Dose adjustments are not required in elder patients. Limited data are
available in elder patients aged
70 years or above.
_Renal impairment _
Dose adjustments are not required in patients with mild to moderate
renal impairment (creatinine
clearance ≥ 30 mL/min). Spedra is contraindicated in patients with
severe renal impairment (creatinine
clearance < 30 mL/min) (see sections 4.3 and 5.2). Patients with mild
or moderate renal impairment
(creatinine clearance ≥30 mL/min but <80 mL/min) who were enrolled
in phase 3 studies showed
decreased efficacy compared to those with normal renal function.
_Hepatic impairment _
Spedra is contraindicated in patients with severe hepatic impairment
(Child Pugh class C) (see
sections 4.3 and 5.2). Patients with mild to moderate hepatic
impairment (Child-Pugh class A or B)
should initiate treatment with the minimum efficacious dose and adjust
posology based on tolerance.
_Use in men with diabetes _
Dose adjustments are not required in diabetic patients.
3
_Paediatric population _
There is no relevant use of Spedra i
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 24-11-2021
Ciri produk Ciri produk Bulgaria 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 10-03-2015
Risalah maklumat Risalah maklumat Sepanyol 24-11-2021
Ciri produk Ciri produk Sepanyol 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 10-03-2015
Risalah maklumat Risalah maklumat Czech 24-11-2021
Ciri produk Ciri produk Czech 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Czech 10-03-2015
Risalah maklumat Risalah maklumat Denmark 24-11-2021
Ciri produk Ciri produk Denmark 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 10-03-2015
Risalah maklumat Risalah maklumat Jerman 24-11-2021
Ciri produk Ciri produk Jerman 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 10-03-2015
Risalah maklumat Risalah maklumat Estonia 24-11-2021
Ciri produk Ciri produk Estonia 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 10-03-2015
Risalah maklumat Risalah maklumat Greek 24-11-2021
Ciri produk Ciri produk Greek 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Greek 10-03-2015
Risalah maklumat Risalah maklumat Perancis 24-11-2021
Ciri produk Ciri produk Perancis 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 10-03-2015
Risalah maklumat Risalah maklumat Itali 24-11-2021
Ciri produk Ciri produk Itali 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Itali 10-03-2015
Risalah maklumat Risalah maklumat Latvia 24-11-2021
Ciri produk Ciri produk Latvia 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 10-03-2015
Risalah maklumat Risalah maklumat Lithuania 24-11-2021
Ciri produk Ciri produk Lithuania 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 10-03-2015
Risalah maklumat Risalah maklumat Hungary 24-11-2021
Ciri produk Ciri produk Hungary 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 10-03-2015
Risalah maklumat Risalah maklumat Malta 24-11-2021
Ciri produk Ciri produk Malta 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Malta 10-03-2015
Risalah maklumat Risalah maklumat Belanda 24-11-2021
Ciri produk Ciri produk Belanda 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 10-03-2015
Risalah maklumat Risalah maklumat Poland 24-11-2021
Ciri produk Ciri produk Poland 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Poland 10-03-2015
Risalah maklumat Risalah maklumat Portugis 24-11-2021
Ciri produk Ciri produk Portugis 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 10-03-2015
Risalah maklumat Risalah maklumat Romania 24-11-2021
Ciri produk Ciri produk Romania 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Romania 10-03-2015
Risalah maklumat Risalah maklumat Slovak 24-11-2021
Ciri produk Ciri produk Slovak 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 10-03-2015
Risalah maklumat Risalah maklumat Slovenia 24-11-2021
Ciri produk Ciri produk Slovenia 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 10-03-2015
Risalah maklumat Risalah maklumat Finland 24-11-2021
Ciri produk Ciri produk Finland 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Finland 10-03-2015
Risalah maklumat Risalah maklumat Sweden 24-11-2021
Ciri produk Ciri produk Sweden 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 10-03-2015
Risalah maklumat Risalah maklumat Norway 24-11-2021
Ciri produk Ciri produk Norway 24-11-2021
Risalah maklumat Risalah maklumat Iceland 24-11-2021
Ciri produk Ciri produk Iceland 24-11-2021
Risalah maklumat Risalah maklumat Croat 24-11-2021
Ciri produk Ciri produk Croat 24-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Croat 10-03-2015

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen